Q-omics provides the consensus-scored DPY19L2 profile across patient tissues and cancer cell-line models. DPY19L2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, DPY19L2 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, DPY19L2 RNA expression shows 18,668 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight PAAD, THCA, and UVM as cancer lineages where DPY19L2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DPY19L2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DPY19L2 survival associations across molecular data types. DPY19L2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DPY19L2 RNA expression–survival associations across cancer types. High DPY19L2 expression shows unfavorable associations in COAD, but favorable associations in PAAD, LAML, LUSC, HNSC and THYM. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify PAAD as the clearest survival context for DPY19L2 RNA expression.
This table summarizes DPY19L2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for DPY19L2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DPY19L2 shows lower tumor expression in THCA, BLCA, UCEC, BRCA, STAD and COAD. The THCA box plot shows higher DPY19L2 RNA expression in normal versus tumor tissue (log2 FC = −2.168, t-test p < 0.001).
This table shows molecular features associated with DPY19L2 in patient tissues and cancer cell lines. In patient samples, DPY19L2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, DPY19L2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and OVARY.
